LONDON – Acacia Pharma Ltd. will go public on the London Stock Exchange with the aim of raising £150 million (US$231 million) to complete development and begin commercialization of its two lead products for treating postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV).